On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 01/30/23
- Vera Therapeutics reports Phase 2 results of atacicept in IgA nephropathy
- 01/25/23
- Vera Therapeutics to host KOL webinar on atacicept
- 01/03/23
- Vera Therapeutics shares fall 67% despite ORIGIN trial meeting primary endpoint
- 01/03/23
- Vera Therapeutics announces ORIGIN clinical trial met primary endpoint
- 02/01/23
- Tenax receives NOA from USPTO for patent for levosimendan in PH-HFpEF
- 01/04/23
- Tenax Therapeutics announces 1-for-20 reverse stock split
- 10/10/22
- Tenax Therapeutics announces presentation of data from study of levosimendan
- 09/15/22
- Tenax Therapeutics trading resumes
- 01/04/23
- Roivant Sciences up 9% in pre-market at $7.78 after RVT-3101 phase 2b study data
- 01/04/23
- Roivant Sciences announces 'positive' results from Phase 2b study of RVT-3101
- 12/01/22
- Roivant Sciences, Pfizer form new Vant company focused on developing RVT-3101
- 11/10/22
- Roivant's Affivant to present data on AFVT-2101 at SITC
- 11/28/22
- Qorvo partners with MediaTek to secure design wins
- 11/02/22
- Qorvo, SK Siltron CSS enter SiC supply agreement
- 11/02/22
- Qorvo announces $2B share repurchase program
- 08/30/22
- Qorvo appoints Grant Brown as CFO
- 11/17/22
- PTC to acquire ServiceMax for $1.46B in cash
- 11/14/22
- Lone Pine adds Autodesk stake, reduces Meta Platforms, Microsoft stakes
- 10/19/22
- MaxLinear, SoftAtHome team on prpl LCM solution for home gateways
- 09/01/22
- Digi International selects MaxLinear PCIe bridges, serial transceivers
- 08/31/22
- Silicon Motion shareholders approve acquisition by MaxLinear
- $153.10 /
+4.135 (+2.78%) - 02/01/23
- Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B
- 02/01/23
- Meta says 2023 will be 'a year of efficiency'
- 02/01/23
- Meta Platforms announces $40B increase in share repurchase authorization
- 02/01/23
- Meta Platforms reports FoA and RL segment restructuring charges
- 09/29/22
- McKesson extends pharmaceutical distribution agreement with CVS Health
- 09/19/22
- McKesson signs agreement to acquire Rx Savings Solutions
- 09/19/22
- McKesson to acquire Rx Savings Solutions for $600M upfront
- 09/13/22
- McKesson names LeAnn Smith chief human resources officer
- 12/30/22
- Intevac signs joint development agreement with glass, glass ceramic provider
- 10/26/22
- Intevac gets $12M order for hard disk drive technology upgrades
- 12/06/22
- Hologic's new data identifies patients benefiting from endocrine therapy
- 11/25/22
- Hologic to showcase portfolio of breast, skeletal health solutions at RSNA 2022
- 11/02/22
- Hologic awarded $19M BARDA contract
- 10/23/22
- Fly Intel: Top five weekend stock stories
- 12/05/22
- Ezcorp increases investment in Florida and Caribbean
- 11/17/22
- EZCORP trading resumes
- 11/17/22
- EZCORP trading halted, volatility trading pause
- 08/22/22
- Ezcorp launches Buy More, Earn More promotion
- 11/03/22
- e.l.f. Beauty rises 10.2%
- 01/18/23
- 8x8 announces approximately 7% reduction in workforce
- 12/13/22
- Matterport appoints Matthew Zinn as chief legal officer
- 12/08/22
- Spearline acquires Callstats from 8x8, terms not disclosed
- 11/30/22
- 8x8 terminates CEO Dave Sipes, Samuel Wilson named interim CEO
- 12/20/22
- Corteva Agriscience, Nevonex announce collaboration agreement
- 11/30/22
- Corteva to acquire Stoller Group for $1.2B
- 11/14/22
- Starboard takes stake in Wix.com, exits Elanco Animal Health
- 10/03/22
- Syngenta, Corteva sued by FTC for pay-to-black scheme
- 01/17/23
- Core Laboratories proposes redomestication of parent company to U.S.
- 10/26/22
- Core Laboratories CEO sees progress in onshore and offshore client activity
- 10/05/22
- ChampionX's US Synthetic weighs challenge to patent ruling
- 09/29/22
- ChampionX publishes first sustainability report
- $101.99 /
+1.755 (+1.75%) - 02/01/23
- C.H. Robinson sees 2023 capital expenditures $90M-$100M
- 01/03/23
- C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO
- 11/17/22
- C.H. Robinson raises quarterly dividend to 61c per share from 55c
- 11/02/22
- C.H. Robinson sees $175M of gross cost savings in Q4
- 10/27/22
- Century Communities falls -12.0%
- 10/26/22
- Century Communities CFO provides FY22 outlook
- $282.22 /
+12.72 (+4.72%) - 02/01/23
- Align Technology board authorizes $1B buyback to succeed current program
- 10/31/22
- Align Technology CEO Joe Hogan to purchase additional $2M of common stock
- 10/31/22
- Align Technology announces $200M accelerated share repurchase agreement
- 10/26/22
- Align Technology falls 20% to $177.50 after Q3 results misses estimates
- $153.10 /
+4.135 (+2.78%) - 01/31/23 LightShed Partners
- Meta Platforms initiated with a Buy at LightShed Partners
- 01/30/23 DA Davidson
- DA Davidson neutral on Pinterest ahead of earnings
- 01/27/23 BofA
- BuzzFeed still a 'show me story,' Meta deal not new, says BofA
- 01/26/23 Piper Sandler
- Meta Platforms price target raised to $136 from $116 at Piper Sandler
- $282.22 /
+12.72 (+4.72%) - 01/11/23 Piper Sandler
- Align Technology price target raised to $255 from $230 at Piper Sandler
- 10/27/22 Stifel
- Align Technology price target lowered to $265 from $325 at Stifel
- 10/27/22 Baird
- Align Technology price target lowered to $260 from $310 at Baird
- 10/27/22 Piper Sandler
- Align Technology price target lowered to $230 from $300 at Piper Sandler
- 01/24/23 Stifel
- e.l.f. Beauty price target raised to $50 from $43 at Stifel
- 01/13/23 JPMorgan
- e.l.f. Beauty price target raised to $65 from $62 at JPMorgan
- 01/09/23 Jefferies
- e.l.f. Beauty downgraded to Hold from Buy at Jefferies
- 01/03/23 Piper Sandler
- e.l.f. Beauty price target raised to $64 from $55 at Piper Sandler
- 01/04/23 Canaccord
- Canaccord starts Ezcorp with a Buy, says discount 'undeserved'
- 01/04/23 Canaccord
- Ezcorp initiated with a Buy at Canaccord
- 04/05/22 Jefferies
- Ezcorp upgraded to Buy from Hold at Jefferies
- 12/15/22 Wedbush
- Wedbush starts 8x8 with a Neutral as momentum slows
- 12/14/22 Wedbush
- 8x8 initiated with a Neutral at Wedbush
- 12/02/22 Craig-Hallum
- Craig-Hallum sees 'tremendous logic' in RingCentral, 8x8 combination
- 10/28/22 Barclays
- 8x8 price target lowered to $4 from $5 at Barclays
- 01/03/23 Benchmark
- Intevac upgraded to Buy at Benchmark following TRIO agreement
- 01/03/23 Benchmark
- Intevac upgraded to Buy from Hold at Benchmark
- 02/10/22 Benchmark
- Intevac downgraded to Hold from Buy at Benchmark
- 01/24/23 Mizuho
- Hologic price target raised to $90 from $77 at Mizuho
- 01/10/23 Wells Fargo
- Hologic price target raised to $80 from $75 at Wells Fargo
- 12/06/22 RBC Capital
- Hologic initiated with a Sector Perform at RBC Capital
- 11/16/22 Evercore ISI
- Evercore ISI removes seven Healthcare Services and Tech stocks from 'TAP' list
- 01/09/23 BofA
- Core Laboratories upgraded to Neutral from Underperform at BofA
- 10/07/22 Piper Sandler
- Core Laboratories assumed with a Neutral at Piper Sandler
- 10/06/22 Citi
- Citi upgrades Core Laboratories to Neutral following pullback
- 10/06/22 Citi
- Core Laboratories upgraded to Neutral from Sell at Citi
- 01/31/23 UBS
- McKesson price target lowered to $440 from $450 at UBS
- 01/11/23 Baird
- McKesson price target raised to $445 from $440 at Baird
- 11/14/22 Mizuho
- McKesson price target raised to $376 from $345 at Mizuho
- 11/02/22 TD Cowen
- McKesson price target raised to $416 from $384 at Cowen
- 11/01/22 Citi
- ChampionX price target raised to $34 from $30 at Citi
- 10/07/22 Piper Sandler
- ChampionX assumed with an Overweight at Piper Sandler
- 10/06/22 Barclays
- ChampionX downgraded on less potential upside potential at Barclays
- 10/06/22 Barclays
- ChampionX downgraded to Equal Weight from Overweight at Barclays
- 11/02/22 Needham
- Silicon Motion upgraded to Buy at Needham after 'better than feared' report
- 10/26/22 Northland
- MaxLinear price target lowered to $35 from $45 at Northland
- 10/26/22 Craig-Hallum
- MaxLinear price target lowered to $55 from $65 at Craig-Hallum
- 10/26/22 Susquehanna
- MaxLinear price target lowered to $42 from $45 at Susquehanna
- 01/30/23 RBC Capital
- PTC price target raised to $155 from $140 at RBC Capital
- 01/26/23 Baird
- PTC price target raised to $165 from $150 at Baird
- 01/23/23 KeyBanc
- PTC upgraded to Overweight from Sector Weight at KeyBanc
- 01/11/23 Barclays
- PTC price target lowered to $144 from $148 at Barclays
- $101.99 /
+1.755 (+1.75%) - 01/17/23 BofA
- Schneider, Werner upgraded to Buy, XPO Logistics downgraded at BofA
- 01/17/23 BofA
- C.H. Robinson downgraded to Underperform from Neutral at BofA
- 01/11/23 JPMorgan
- C.H. Robinson downgraded to Neutral from Overweight at JPMorgan
- 01/11/23 KeyBanc
- C.H. Robinson price target lowered to $110 from $120 at KeyBanc
- 01/20/23 Citi
- Corteva price target lowered to $72 from $75 at Citi
- 01/18/23 Wells Fargo
- Corteva initiated with an Overweight at Wells Fargo
- 01/18/23 Wells Fargo
- Corteva initiated with an Overweight at Wells Fargo
- 01/11/23
- BofA shakes up ratings to get 'more offensive' in U.S. Chemicals
- 01/23/23 Barclays
- Qorvo price target raised to $110 from $85 at Barclays
- 01/17/23 Citi
- Citi opens 'positive catalyst watch' on Qorvo
- 01/11/23 KeyBanc
- KeyBanc says iPhone survey shows supply partial recovery, some shortages remain
- 01/09/23 Wells Fargo
- Qorvo price target raised to $90 from $80 at Wells Fargo
- 01/20/23 B. Riley
- Century Communities price target raised to $49 from $44 at B. Riley
- 12/30/22 Wedbush
- Wedbush favors four homebuilding stocks heading into 2023
- 11/29/22 BTIG
- Century Communities initiated with a Neutral at BTIG
- 11/22/22 JPMorgan
- Century Communities downgraded to Underweight from Overweight at JPMorgan
- 01/04/23 Jefferies
- Vera Therapeutics downgraded to Hold from Buy at Jefferies
- 01/04/23 Wedbush
- Wedbush downgrades Vera Therapeutics to Neutral, lowers price target to $8
- 01/04/23 Wedbush
- Vera Therapeutics downgraded to Neutral from Outperform at Wedbush
- 01/04/23 H.C. Wainwright
- Vera Therapeutics price target lowered to $15 from $36 at H.C. Wainwright
- 01/05/23 Citi
- Roivant Sciences price target raised to $14 from $11 at Citi
- 01/04/23 Piper Sandler
- Prometheus, Roivant TL1A data look 'highly competitive,' says Piper
- 12/28/22 Cantor Fitzgerald
- Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
- 12/27/22 Cantor Fitzgerald
- Roivant's upcoming data readouts could move stock higher, says Cantor Fitzgerald
- 11/09/22
- Vera Therapeutics reports Q3 EPS (91c), consensus (72c)
- 08/10/22
- Vera Therapeutics reports Q2 EPS (55c) vs (33c) last year
- 11/14/22
- Roivant Sciences reports Q2 EPS (42c), consensus (41c)
- 08/15/22
- Roivant Sciences reports Q1 EPS (48c) vs (13c) last year
- 02/01/23
- Qorvo sees Q4 EPS 10c-15c, consensus 64c
- 02/01/23
- Qorvo reports Q3 EPS 75c, consensus 63c
- 11/02/22
- Qorvo sees Q3 EPS 50c-75c, consensus $1.69
- 02/01/23
- PTC raises FY23 revenue view to $2.070B-$2.150B from $2.050B-$2.130B
- 02/01/23
- PTC reports Q1 adjusted EPS 99c, consensus $1.03
- 11/02/22
- PTC sees FY23 revenue $1.91B-$1.99B, consensus $1.92B
- 11/02/22
- PTC reports Q4 adjusted EPS $1.27, consensus $1.15
- 02/01/23
- MaxLinear sees Q1 revenue $240M-$260M, consesus $279.7M
- 02/01/23
- MaxLinear reports Q4 adjusted EPS $1.07, consensus $1.06
- 10/25/22
- MaxLinear sees Q4 revenue $285M-$295M, consensus $285.36M
- 10/25/22
- MaxLinear reports Q3 EPS $1.05, consensus $1.04
- $153.10 /
+4.135 (+2.78%) - 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 02/01/23
- McKesson raises FY23 EPS view to $25.75-$26.15 from $24.45-$24.95
- 02/01/23
- McKesson reports Q3 adjusted EPS $6.90, consensus $6.35
- 11/01/22
- McKesson boosts FY23 adjusted EPS view to $24.45-$24.95 from $23.95-$24.65
- 02/01/23
- Intevac sees Q1 EPS (20c)-(16c), consensus (21c)
- 02/01/23
- Intevac reports Q4 EPS (13c) vs. (25c) y/y
- 11/02/22
- Intevac sees Q4 EPS (21c)-(17c), consensus (12c)
- 08/03/22
- Intevac sees Q3 EPS (17c) to (15c), one estimate (13c)
- 02/01/23
- Hologic raises FY23 EPS view to $3.55-$3.85 from $3.30-$3.60
- 02/01/23
- Hologic sees Q2 adjusted EPS 80c-90c, consensus 82c
- 02/01/23
- Hologic reports Q1 adjusted EPS $1.07, consensus 91c
- 01/08/23
- Hologic reports preliminary Q1 revenue $1.074B, consensus $966.37M
- 02/01/23
- Ezcorp reports Q1 adjusted EPS 28c, consensus 22c
- 11/16/22
- Ezcorp reports Q4 adjusted EPS 15c, one estimate 12c
- 08/03/22
- Ezcorp reports Q3 adjusted EPS 16c, consensus 5c
- 02/01/23
- e.l.f. Beauty raises FY23 adjusted EPS view to $1.37-$1.40 from $1.07-$1.10
- 02/01/23
- e.l.f. Beauty reports Q3 adjusted EPS 48c, consensus 23c
- 11/02/22
- e.l.f. Beauty raises FY23 EPS view to $1.07-$1.10 from 84c-87c
- 11/02/22
- e.l.f. Beauty reports Q2 EPS 36c, consensus 16c
- 02/01/23
- 8x8 raises FY23 revenue view to $743.4M-$746.4M from $720M-$730M
- 02/01/23
- 8x8 sees Q4 revenue $184M-$187M, consensus $187.67M
- 02/01/23
- 8x8 reports Q3 adjusted EPS 7c, consensus 3c
- 02/01/23
- Corteva sees FY23 operating EPS $2.70-$2.90, consensus $3.13
- 02/01/23
- Corteva reports Q4 adjusted EPS 16c, consensus 5c
- 11/03/22
- Corteva backs FY22 adjusted EPS view $2.45-$2.60, consensus $2.57
- 11/03/22
- Corteva reports Q3 adjusted EPS (12c), consensus (23c)
- 02/01/23
- Core Laboratories reports Q4 EPS 20c, consensus 20c
- 10/26/22
- Core Laboratories reports Q3 EPS 18c, consensus 15c
- 02/01/23
- ChampionX sees Q1 revenue $952M-$982M, consensus $994.58M
- 02/01/23
- ChampionX reports Q4 EPS 33c, consensus 40c
- 10/25/22
- ChampionX sees Q4 revenue $985M-$1.015B, consensus $953.01M
- 10/25/22
- ChampionX reports Q3 adjusted EPS 33c, consensus 32c
- $101.99 /
+1.755 (+1.75%) - 02/01/23
- C.H. Robinson reports Q4 adjusted EPS $1.03, consensus $1.38
- 11/02/22
- C.H. Robinson reports Q3 EPS $1.78, consensus $2.17
- 02/01/23
- Century Communities reports Q4 adjusted EPS $2.71, consensus $2.43
- 10/26/22
- Century Communities reports Q3 EPS $4.44, consensus $4.20
- $282.22 /
+12.72 (+4.72%) - 02/01/23
- Align Technology reports Q4 EPS $1.73, consensus $1.56
- 10/26/22
- Align Technology reports Q3 adjusted EPS $1.36, consensus $2.18
|
Earnings
|
Reports Q4 revenue… Reports Q4 revenue $290.6M, consensus $290.05M. "In the fourth quarter, we continued our strong execution with revenue up 2% sequentially and up 17% year-over-year, bringing fiscal 2022 revenues to over $1 billion. In particular, in Q4, our Wi-Fi business delivered substantial sequential and year-over-year growth. Our connectivity category almost doubled in Q4 year-over-year, driven by our differentiated Wi-Fi6 feature set. Our results included strong cash flows from operations of approximately $69 million in Q4 and approximately $389 million for the full year. Over the last two years, we have delivered transformative growth and strong financials while balancing disciplined expense management along with investments in technology innovation. Now, as we enter 2023, we have conviction in our strong long-term growth prospects, owing to our developing technology leadership, accelerating design-win momentum, and expanding target markets, including Wi-Fi, fiber access, wireless and optical infrastructure. We are also looking forward to our pending acquisition of Silicon Motion, and are excited for the future growth opportunities of our comprehensive product portfolio," commented Kishore Seendripu, Ph.D., Chairman and CEO. ShowHide Related Items >><< - 10/19/22
- MaxLinear, SoftAtHome team on prpl LCM solution for home gateways
- 09/01/22
- Digi International selects MaxLinear PCIe bridges, serial transceivers
- 08/31/22
- Silicon Motion shareholders approve acquisition by MaxLinear
- 11/02/22 Needham
- Silicon Motion upgraded to Buy at Needham after 'better than feared' report
- 10/26/22 Northland
- MaxLinear price target lowered to $35 from $45 at Northland
- 10/26/22 Craig-Hallum
- MaxLinear price target lowered to $55 from $65 at Craig-Hallum
- 10/26/22 Susquehanna
- MaxLinear price target lowered to $42 from $45 at Susquehanna
- 10/25/22
- MaxLinear sees Q4 revenue $285M-$295M, consensus $285.36M
- 10/25/22
- MaxLinear reports Q3 EPS $1.05, consensus $1.04
- 10/25/22
- Notable companies reporting after market close
- 10/25/22
- Fly Intel: After-Hours Movers
- 10/05/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|